NCT03471260View on ClinicalTrials.gov

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Ivosidenib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (4)

44195

RECRUITING

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

77030

RECRUITING

M D Anderson Cancer Center, Houston

97239

RECRUITING

Oregon Health and Science University, Portland

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER